Brazikumab

Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease.[1][2]

Brazikumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL23
Clinical data
Other namesMEDI2070
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6410H9830N1718O2016S50
Molar mass144820.16 g·mol−1

This drug was developed by MedImmune.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.